Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 10.46 USD 5.13% Market Closed
Market Cap: 399.8m USD

Operating Margin
Entrada Therapeutics Inc

-197.6%
Current
-57%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-197.6%
=
Operating Profit
-121.6m
/
Revenue
61.5m

Operating Margin Across Competitors

No Stocks Found

Entrada Therapeutics Inc
Glance View

Market Cap
399.8m USD
Industry
Biotechnology

Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

TRDA Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-197.6%
=
Operating Profit
-121.6m
/
Revenue
61.5m
What is the Operating Margin of Entrada Therapeutics Inc?

Based on Entrada Therapeutics Inc's most recent financial statements, the company has Operating Margin of -197.6%.

Back to Top